Engineered immune cells take on Hard-to-Treat lymphoma
Disease control
Recruiting now
This early-stage trial tests a new treatment called Senza5 CART5 for people with a type of T cell lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells. Th…
Phase: PHASE1 • Sponsor: Vittoria Biotherapeutics • Aim: Disease control
Last updated May 17, 2026 11:51 UTC